RESEARCH TRIANGLE PARK, N.C. — New Phase 2 clinical data from Japan found that pediatric and adolescent and young adult (AYA) patients receiving PEDMARK® (sodium thiosulfate) following cisplatin chemotherapy experienced a significantly lower rate of hearing loss compared with a prespecified historical benchmark....
Continue reading at Hearing Health Matters
✦ The floor
Discussion
Signed responses from readers of the wire.
This Phase 2 result from Japan adds geographic replication to existing evidence for sodium thiosulfate as a hearing protectant in pediatric cisplatin patients, but audiologists should await peer-reviewed publication and regulatory guidance before changing referral or monitoring protocols.
Cisplatin-induced hearing loss is a major survivorship burden in pediatric oncology, and replication of PEDMARK's protective effect in a Japanese cohort could support broader international adoption and reinforce audiologists' role in monitoring and advocacy for otoprotective protocols.
- 01Japanese Phase 2 study found PEDMARK (sodium thiosulfate) significantly reduced cisplatin-related hearing loss in pediatric and young adult patients.
- 02PEDMARK is administered after cisplatin chemotherapy as an otoprotective (hearing-protective) agent.
- 03The study adds international evidence to prior trials (e.g., SIOPEL 6) supporting sodium thiosulfate efficacy.
- 04The report originates from a press release via a blog — peer-reviewed data not yet confirmed in the article.
- 05Fennec Pharmaceuticals, the PEDMARK manufacturer, appears to be the source of the announcement.
Pediatric and adolescent/young adult patients receiving PEDMARK after cisplatin had a significantly lower rate of cisplatin-induced hearing loss compared to controls.
press releasepartially supported